Journal of Clinical Oncology, Vol 17, Issue 5
(May), 1999: 1499
© 1999 American Society for Clinical Oncology
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer
Michael W. Kattan,
Thomas M. Wheeler,
Peter T. Scardino
From the Departments of Epidemiology and Biostatistics and Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Pathology, Baylor College of Medicine; and The Methodist Hospital, Houston, TX.
Address reprint requests to Peter T. Scardino, MD, c/o Brenna Nichols, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; email nicholsb{at}mskcc.org
PURPOSE: Although models exist that place patients into discrete groups at various risks for disease recurrence after surgery for prostate cancer, we know of no published work that combines pathologic factors to predict an individual's probability of disease recurrence. Because clinical stage and biopsy Gleason grade only approximate pathologic stage and Gleason grade in the prostatectomy specimen, prediction of prognosis should be more accurate when postoperative information is added to preoperative variables. Therefore, we developed a postoperative nomogram that allows more accurate prediction of probability for disease recurrence for patients who have received radical prostatectomy as treatment for prostate cancer, compared with the preoperative nomogram we previously published.
PATIENTS AND METHODS: By Cox proportional hazards regression analysis, we modeled the clinical and pathologic data and disease follow-up for 996 men with clinical stage T1a-T3c NXM0 prostate cancer who were treated with radical prostatectomy by a single surgeon at our institution. Prognostic variables included pretreatment serum prostate-specific antigen level, specimen Gleason sum, prostatic capsular invasion, surgical margin status, seminal vesicle invasion, and lymph node status. Treatment failure was recorded when there was either clinical evidence of disease recurrence, a rising serum prostate-specific antigen level (two measurements of 0.4 ng/mL or greater and rising), or initiation of adjuvant therapy. Validation was performed on this set of men and a separate sample of 322 men from five other surgeons' practices from our institution.
RESULTS: Cancer recurrence was noted in 189 of the 996 men, and the recurrence-free group had a median follow-up period of 37 months (range, 1 to 168 months). The 7-year recurrence-free probability for the cohort was 73% (95% confidence interval, 68% to 76%). The predictions from the nomogram appeared to be accurate and discriminating, with a validation sample area under the receiver operating characteristic curve (ie, a comparison of the predicted probability with the actual outcome) of 0.89.
CONCLUSION: A postoperative nomogram has been developed that can be used to predict the 7-year probability of disease recurrence among men treated with radical prostatectomy.
A PalmPilot version of this nonogram is available free of charge at http://nomograms.org.
This article has been cited by other articles:
|
|
|
|
 
S. F. Shariat, P. I. Karakiewicz, N. Suardi, and M. W. Kattan
Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature
Clin. Cancer Res.,
July 15, 2008;
14(14):
4400 - 4407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, J. Walz, C. G. Roehrborn, A. R. Zlotta, P. Perrotte, N. Suardi, F. Saad, and P. I. Karakiewicz
External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy
J. Clin. Oncol.,
March 20, 2008;
26(9):
1526 - 1531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wang, Y. Mazaheri, J. Zhang, N. M. Ishill, K. Kuroiwa, and H. Hricak
Assessment of Biologic Aggressiveness of Prostate Cancer: Correlation of MR Signal Intensity with Gleason Grade after Radical Prostatectomy
Radiology,
December 1, 2007;
246(1):
168 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Vickers, F. J. Bianco, A. M. Serio, J. A. Eastham, D. Schrag, E. A. Klein, A. M. Reuther, M. W. Kattan, J. E. Pontes, and P. T. Scardino
The Surgical Learning Curve for Prostate Cancer Control After Radical Prostatectomy
J Natl Cancer Inst,
August 1, 2007;
99(15):
1171 - 1177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al.
Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy
Clin. Cancer Res.,
July 15, 2007;
13(14):
4130 - 4138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, J. Cortes, D. Thomas, G. Garcia-Manero, C. Koller, et al.
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
Blood,
June 1, 2007;
109(11):
4679 - 4685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. I. Karakiewicz, A. Briganti, F. K.-H. Chun, Q.-D. Trinh, P. Perrotte, V. Ficarra, L. Cindolo, A. De La Taille, J. Tostain, P. F.A. Mulders, et al.
Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram
J. Clin. Oncol.,
April 10, 2007;
25(11):
1316 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hricak, P. L. Choyke, S. C. Eberhardt, S. A. Leibel, and P. T. Scardino
Imaging Prostate Cancer: A Multidisciplinary Perspective
Radiology,
April 1, 2007;
243(1):
28 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Lilja, A. Vickers, and P. Scardino
Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer
J. Clin. Oncol.,
February 1, 2007;
25(4):
347 - 348.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, A. Vazina, P. J. Bastian, A. Gupta, A. I. Sagalowsky, et al.
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6663 - 6676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lessard, P. I. Karakiewicz, P. Bellon-Gagnon, M. Alam-Fahmy, H. A. Ismail, A.-M. Mes-Masson, and F. Saad
Nuclear Localization of Nuclear Factor-{kappa}B p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5741 - 5745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sella, L. H. Schwartz, and H. Hricak
Retained Seminal Vesicles After Radical Prostatectomy: Frequency, MRI Characteristics, and Clinical Relevance
Am. J. Roentgenol.,
February 1, 2006;
186(2):
539 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rosenbaum, M. O. Hoque, Y. Cohen, M. Zahurak, M. A. Eisenberger, J. I. Epstein, A. W. Partin, and D. Sidransky
Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy
Clin. Cancer Res.,
December 1, 2005;
11(23):
8321 - 8325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr, Z. A. Dotan, C. J. DiBlasio, A. Reuther, E. A. Klein, and M. W. Kattan
Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy
J. Clin. Oncol.,
October 1, 2005;
23(28):
7005 - 7012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schoder, K. Herrmann, M. Gonen, H. Hricak, S. Eberhard, P. Scardino, H. I. Scher, and S. M. Larson
2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy
Clin. Cancer Res.,
July 1, 2005;
11(13):
4761 - 4769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Zakian, K. Sircar, H. Hricak, H.-N. Chen, A. Shukla-Dave, S. Eberhardt, M. Muruganandham, L. Ebora, M. W. Kattan, V. E. Reuter, et al.
Correlation of Proton MR Spectroscopic Imaging with Gleason Score Based on Step-Section Pathologic Analysis after Radical Prostatectomy
Radiology,
March 1, 2005;
234(3):
804 - 814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M.G. Taylor, M. Yu, and H. M. Sandler
Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer
J. Clin. Oncol.,
February 1, 2005;
23(4):
816 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hoang, R. Xu, J. H. Schiller, P. Bonomi, and D. H. Johnson
Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data
J. Clin. Oncol.,
January 1, 2005;
23(1):
175 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sella, L. H. Schwartz, P. W. Swindle, C. N. Onyebuchi, P. T. Scardino, H. I. Scher, and H. Hricak
Suspected Local Recurrence after Radical Prostatectomy: Endorectal Coil MR Imaging
Radiology,
May 1, 2004;
231(2):
379 - 385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin
Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression
Clin. Cancer Res.,
March 15, 2004;
10(6):
1992 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Beer, M. Garzotto, B. A. Lowe, W. J. Ellis, M. A. Montalto, P. H. Lange, and C. S. Higano
Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer
Clin. Cancer Res.,
February 15, 2004;
10(4):
1306 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. D'Amico, J. W. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen
Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy
J Natl Cancer Inst,
September 17, 2003;
95(18):
1376 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Henshall, D. E. H. Afar, J. Hiller, L. G. Horvath, D. I. Quinn, K. K. Rasiah, K. Gish, D. Willhite, J. G. Kench, M. Gardiner-Garden, et al.
Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse
Cancer Res.,
July 15, 2003;
63(14):
4196 - 4203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Kattan
Judging New Markers by Their Ability to Improve Predictive Accuracy
J Natl Cancer Inst,
May 7, 2003;
95(9):
634 - 635.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Thomas, P. T. Bradshaw, B. H. Pollock, J. E. Montie, J. M.G. Taylor, H. D. Thames, P. W. McLaughlin, D. A. DeBiose, D. H. Hussey, and R. L. Wahl
Indium-111-Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy
J. Clin. Oncol.,
May 1, 2003;
21(9):
1715 - 1721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin
Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein
J. Clin. Oncol.,
April 1, 2003;
21(7):
1223 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Morris and H. I. Scher
Clinical Approaches to Osseous Metastases in Prostate Cancer
Oncologist,
April 1, 2003;
8(2):
161 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. D'Amico, K. Cote, M. Loffredo, A. A. Renshaw, and D. Schultz
Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer
J. Clin. Oncol.,
December 1, 2002;
20(23):
4567 - 4573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nunez, H. A. Macapinlac, H. W.D. Yeung, T. Akhurst, S. Cai, I. Osman, M. Gonen, E. Riedel, H. I. Scher, and S. M. Larson
Combined 18F-FDG and 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate Cancer
J. Nucl. Med.,
January 1, 2002;
43(1):
46 - 55.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, A.-M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O'Neill, J. J. Turner, W. Delprado, et al.
Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models
J. Clin. Oncol.,
August 15, 2001;
19(16):
3692 - 3705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Henshall, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland
Overexpression of the Cell Cycle Inhibitor p16INK4A in High-grade Prostatic Intraepithelial Neoplasia Predicts Early Relapse in Prostate Cancer Patients
Clin. Cancer Res.,
March 1, 2001;
7(3):
544 - 550.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. R. Thornbury, D. K. Ornstein, P. L. Choyke, C. P. Langlotz, and J. C. Weinreb
Prostate Cancer: What Is the Future Role for Imaging?
Am. J. Roentgenol.,
January 1, 2001;
176(1):
17 - 22.
[Full Text]
|
|
|
|
|
|
|
M. W. Kattan, M. J. Zelefsky, P. A. Kupelian, P. T. Scardino, Z. Fuks, and S. A. Leibel
Pretreatment Nomogram for Predicting the Outcome of Three-Dimensional Conformal Radiotherapy in Prostate Cancer
J. Clin. Oncol.,
October 19, 2000;
18(19):
3352 - 3359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. D'Amico, R. Whittington, S. B. Malkowicz, Y. H. Wu, M.-H. Chen, M. Hurwitz, P. W. Kantoff, J. E. Tomaszewski, A. A. Renshaw, A. Wein, et al.
Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials
J. Clin. Oncol.,
September 18, 2000;
18(18):
3240 - 3246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Yang, J. Addai, M. Ittmann, T. M. Wheeler, and T. C. Thompson
Elevated Caveolin-1 Levels in African-American versus White-American Prostate Cancer
Clin. Cancer Res.,
September 1, 2000;
6(9):
3430 - 3433.
[Abstract]
[Full Text]
|
|
|
|
